Text Size

Glaucoma Research Foundation to Host Second Annual "Glaucoma 360"

SAN FRANCISCO, CA - November 16, 2012: Glaucoma Research Foundation (GRF) will host the second annual “Glaucoma 360” - a series of three events taking place from January 31 to February 2, 2013 at the historic Palace Hotel in San Francisco. All proceeds from Glaucoma 360 events will support Glaucoma Research Foundation research and education programs. Register online at Glaucoma360.org.

Thomas M. Brunner, President and CEO of Glaucoma Research Foundation, said “this unique series of three events unites medicine, research, industry, and philanthropy with one mission - to find a cure for glaucoma.”

Glaucoma 360 was founded by Adrienne Graves, PhD, and Andrew Iwach, MD, both of whom serve on the Glaucoma Research Foundation Board of Directors. Drs. Graves and Iwach also serve as Co-Chairs for Glaucoma 360. Dr. Iwach, GRF Board Chair and Executive Director at the Glaucoma Center of San Francisco, said “Glaucoma 360 is designed to bring greater awareness to unmet medical needs in glaucoma and to highlight current and novel therapies that will help preserve sight for glaucoma patients.”

The centerpiece of Glaucoma 360 is the New Horizons Forum on February 1, 2013. The meeting is designed to speed the translation of new ideas into improved therapies and diagnostics for glaucoma patients. According to Dr. Adrienne Graves, “A scientist might have a great concept but be unclear on the next steps; an early-stage company may need financing to proceed with clinical trials; and venture capitalists and industry executives are looking for the next opportunity. With this meeting, we are bringing all of these people together for an interactive session to showcase new ideas in glaucoma.” Dr. Iwach added, “We need better solutions to help patients. The New Horizons Forum will help facilitate collaborations, potentially leading to new treatments and advancing progress toward a cure.”

Topics at the 2013 meeting will include new horizons in glaucoma devices, drug delivery and pharmaceuticals, and panel presentations from nationally and internationally respected leaders from ophthalmology, venture capital, pharmaceutical and medical device companies, and government.

Key opinion leaders in glaucoma, business, and medical innovation provide leadership for the second annual Glaucoma 360 New Horizons Forum. Advisors for the 2013 meeting include: Stuart B. Abelson, MBA, President, Chief Executive Officer, Ora, Inc.; Anthony P. Adamis, MD, VP, Global Head of Ophthalmology, Genentech, Inc.; Paul Chaney, President and CEO, PanOptica; George A. Cioffi, MD, Columbia University College of Physicians and Surgeons; Alan Crandall, MD, John A. Moran Eye Center; Emmett Cunningham, MD, PhD, MPH, Partner, Clarus Ventures; Eugene de Juan, MD, Vice Chair, ForSight Labs; David Epstein, MD, MMM, Duke Eye Center; John W. Grunden, PharmD, Regional Director of Medical Affairs, Merck & Co., Inc.; David Guyer, MD, Partner, SV Life Sciences Advisers, LLC; Eve Higginbotham, SM, MD, Association of American Medical Colleges; H. Dunbar Hoskins, Jr., MD, former Exec. VP, American Academy of Ophthalmology; Wende Hutton, General Partner, Canaan Partners; Ralf Kuschnereit, PhD, President and CEO, Carl Zeiss Meditec, Inc.; Eliot Lazar, MS, MD, President, elCON Medical; Paul Lee, MD, JD, Kellogg Eye Center; Richard L. Lindstrom, MD, Founder, Minnesota Eye Consultants, PA; William J. Link, PhD, Managing Director, Versant Ventures; Sabri Markabi, MD, Sr. VP, R&D, and CMO, Alcon Laboratories; James Mazzo, President and CEO, Abbott Medical Optics; J. Casey McGlynn, JD, Partner, Wilson Sonsini Goodrich & Rosati; Gary D. Novack, PhD, President, PharmaLogic Development, Inc.; David E. I. Pyott, Chairman, President, and CEO, Allergan, Inc.; Kuldev Singh, MD, MPH, Stanford University Medical Center; Ellen Strahlman, MD, MHSc, Chief Medical Officer, GlaxoSmithKline; and Ruth D. Williams, MD, President, American Academy of Ophthalmology. The Program Committee includes: Ike Ahmed, MD, FRCSC , University of Toronto; Anne Coleman, MD, PhD, Jules Stein Eye Institute; Neeru Gupta, MD, PhD, MBA, University of Toronto; Larry Haimovitch, Haimovitch Medical Technology Consultants; Mildred M.G. Olivier, MD, Midwest Glaucoma Center, P.C.; L. Jay Katz, MD, Wills Eye Institute; Richard A. Lewis, MD, Grutzmacher, Lewis & Sierra Surgical Eye Specialists; Eydie G. Miller-Ellis, MD, Scheie Eye Institute; Joel S. Schuman, MD, FACS, University of Pittsburgh; Robert Stamper, MD, University of California, San Francisco; James C. Tsai, MD, MBA, FACS, Yale School of Medicine; Steven Vold, MD, Founder and CEO, Vold Vision; Barbara Wirostko, MD, Moran Eye Center, University of Utah.

The three events in Glaucoma 360 are:

  • Catalyst For A Cure (January 31, 2013) - The annual fundraising dinner and gala to benefit Glaucoma Research Foundation and its endeavors to fund innovative research and provide education and support for glaucoma patients and their caregivers. Includes presentation of The Catalyst Award, Glaucoma Research Foundation’s highest honor, to San Francisco philanthropists Frank Stein and Paul S. May.
  • New Horizons Forum (February 1, 2013) - A full day of presentations, panels and discussions featuring CEOs from start-up companies, industry executives, ophthalmic leaders, venture capitalists and the FDA.
  • Glaucoma Symposium CME (February 2, 2013) - Now in its 17th year, this symposium for clinicians highlights the latest advances in glaucoma management, medications and surgical technique. This year’s Shaffer-Hetherington-Hoskins Lecturer is Louis Cantor, MD, the Jay C. and Lucile L. Kahn Professor of Glaucoma Research and Education, and Director of the Glaucoma Service, Indiana University, Indianapolis.

For more information or to register for Glaucoma 360 events, visit www.glaucoma360.org.

About Glaucoma Research Foundation

Founded in 1978 and headquartered in San Francisco, Glaucoma Research Foundation is America’s oldest and most experienced nonprofit dedicated solely to its mission: to prevent vision loss from glaucoma by investing in innovative research, education and support with the ultimate goal of finding a cure. Celebrating its 35th anniversary in 2013, Glaucoma Research Foundation has invested more than $33 million in research to find a cure. More information is available at www.glaucoma.org/about.

Last reviewed on June 25, 2018

Was this helpful? Yes No